SmartPharm’s gene-encoded therapeutics (GET) approach has multiple benefits compared to traditional viral-vectored gene therapy:

  • Minimally immunogenic; does not require immune suppression

  • Re-dosable in patients

  • Scalable, economic cGMP manufacturing

  • Reduced regulatory complexity

Other non-viral GET companies use either DNA or mRNA approaches. SmartPharm’s platform technology includes both technologies so we can address a broad range of therapeutic opportunities.

  • Selects type of nucleic acid based on specific therapeutic target and purpose

  • Protein sequence tuned for use with the specific nucleic acid platform and for the specific therapeutic application

Our Focus

  • Protective treatment for SARS-CoV-2, the cause of coronavirus COVID-19

    Learn more here
  • Eliminating the need for recombinant enzyme replacement therapy in lysosomal storage diseases with a drug candidate in Gaucher disease type 1

    Learn more here
  • New treatments for tissue restoration and regeneration

    Learn More Here

Our Culture and Leadership

  • We have built a dynamic, smart organization around leaders with real-world experience in drug development and medical care

    See our Management Team

    See our Scientific and Clinical Advisors
  • The work of our company is supported and guided by our board

     

Working at SmartPharm